Drug Approval | May 31, 2021
Cadila Healthcare’s margin supported by lower R&D : ICICI Securities
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
US revenues were sequentially stable at US$370mn with steady performance in the specialty portfolio
Cadila's ZyCov-D (DNA-based vaccine) is undergoing phase III trials.
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1140.01 crores during FY 2020-21
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
The GMP certificate is valid for three years until April 2024.
It posted net profit of Rs.60.96 crores for the 12 months period ended March 31, 2021
The company has registered total income of Rs. 3,847 crores for Q4 FY21, up by 3% on a y-o-y basis from Rs. 3,752 crores registered during corresponding period of the previous year
Mucormycosis drug AmphoTLC will be imported from Taiwan by Stelis Biopharma Private Limited (Stelis), the biotech arm of Strides group, and will be launched and distributed in India immediately by Strides
Subscribe To Our Newsletter & Stay Updated
